KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA (2016 - 2025)

Alnylam Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at $113.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 221.15% year-over-year to $113.2 million; the TTM value through Dec 2025 reached $292.5 million, up 201.11%, while the annual FY2025 figure was $328.2 million, 213.44% up from the prior year.
  • EBITDA reached $113.2 million in Q4 2025 per ALNY's latest filing, down from $259.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $259.3 million in Q3 2025 to a low of -$407.5 million in Q3 2022.
  • Average EBITDA over 5 years is -$120.0 million, with a median of -$148.7 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 166.73% in 2024, then soared 354.78% in 2025.
  • A 5-year view of EBITDA shows it stood at -$257.5 million in 2021, then increased by 19.08% to -$208.4 million in 2022, then soared by 38.13% to -$128.9 million in 2023, then increased by 27.5% to -$93.5 million in 2024, then surged by 221.15% to $113.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBITDA are $113.2 million (Q4 2025), $259.3 million (Q3 2025), and -$58.7 million (Q2 2025).